The Structure-Based Design of Mdm2/Mdmx-p53 Inhibitors Gets Serious

Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain

(2014) Grzegorz Popowicz et al.   CELL CYCLE

The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior

(2011) Yan Liu et al.   CELL CYCLE

Dimerization of the core domain of the p53 family: A computational study

(2011) Arumugam Madhumalar et al.   CELL CYCLE

Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment

(2010) Sergey V Tokalov et al.   BMC CANCER

High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx

(2010) Anna Czarna et al.   CELL CYCLE

Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies

(2010) Thomas Leonard Joseph et al.   CELL CYCLE

Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery

(2010) Grzegorz M. Popowicz et al.   CELL CYCLE

Patented inhibitors of p53–Mdm2 interaction (2006 – 2008)

(2010) Lutz Weber   EXPERT OPINION ON THERAPEUTIC PATENTS

Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways

(2010) Tongsen Zheng et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

A Medicinal Chemist’s Guide to Molecular Interactions

(2010) Caterina Bissantz et al.   JOURNAL OF MEDICINAL CHEMISTRY

Role of Mdm4 in drug sensitivity of breast cancer cells

(2010) S Lam et al.   ONCOGENE

Modulating the p53 pathway

(2010) Anwesha Dey et al.   SEMINARS IN CANCER BIOLOGY

The p53 orchestra: Mdm2 and Mdmx set the tone

(2010) Mark Wade et al.   TRENDS IN CELL BIOLOGY

Apamin as a Template for Structure-Based Rational Design of Potent Peptide Activators of p53

(2009) Chong Li et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Signaling to p53: Ribosomal Proteins Find Their Way

(2009) Yanping Zhang et al.   CANCER CELL

Mdm2-mediated ubiquitylation: p53 and beyond

(2009) J-C Marine et al.   CELL DEATH AND DIFFERENTIATION

The multiple levels of regulation by p53 ubiquitination

(2009) J T Lee et al.   CELL DEATH AND DIFFERENTIATION

Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes

(2009) Joerg Kallen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX

(2009) Jason Phan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Rapid and Efficient Hydrophilicity Tuning of p53/mdm2 Antagonists

(2009) Stuti Srivastava et al.   JOURNAL OF COMBINATORIAL CHEMISTRY

Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2−Tumor Protein 53 Protein−Protein Interaction

(2009) John G. Allen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

(2009) M. Pazgier et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural Biology of the Tumor Suppressor p53

(2008) Andreas C. Joerger et al.   Annual Review of Biochemistry

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

(2008) Sanjeev Shangary et al.   Annual Review of Pharmacology and Toxicology

Small molecular weight protein–protein interaction antagonists—an insurmountable challenge?

(2008) Alexander Dömling   CURRENT OPINION IN CHEMICAL BIOLOGY

Multiple Peptide Conformations Give Rise to Similar Binding Affinities: Molecular Simulations of p53-MDM2

(2008) Shubhra Ghosh Dastidar et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Turning a Scorpion Toxin into an Antitumor Miniprotein

(2008) Chong Li et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines

(2008) M Kitagawa et al.   ONCOGENE

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA